July 16, 2014
A New Era in Hepatitis C Treatment
Until recently, treating hepatitis C (HCV) required 24 weeks or more of weekly injections with a regimen including peginterferon alfa. These drug combinations often failed to cure the HCV infection and came with many side effects.
However, it's been a breakthrough year for HCV treatment, with many new, more effective and safer options taking the spotlight. Spearheading the way has been sofosbuvir (Sovaldi), a nucleotide polymerase inhibitor that allows for oral dosing, interferon-free treatment for many and a shorter treatment course.
But the drug's introduction -- and its high baseline price tag -- has stirred considerable debate. Let's examine the brief history of sofosbuvir and how its controversial price could impact future health care costs.
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
No comments have been made.
|Which Hepatitis C Treatment to Start in 2016|
|This Week in HIV Research: Antibody Suppresses HIV; Investigational Drug BMS-986001; and Quality of Care on Mortality|
|This Week in HIV Research: Smoking Associated With Poor HIV Outcomes; How Gay Men Decide on Condomless Sex; and More|
|This Week in HIV Research: Tenofovir Resistance Alarmingly Common; Ongoing HIV Replication Replenishes Reservoirs; and More|
|High Liver Enzymes Signal Serious Disease in HIV-Positive Individuals Without Hepatitis|
|We Aren't the Sex Police: What PrEP Providers Say About Condoms and STIs|